Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Beigene
ApprovedFDA, Mar 2024
1Registered trials
What is Tislelizumab?
Tislelizumab is a monoclonal antibody that binds PD-1 on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, releasing PD-1-mediated inhibition of anti-tumor immune responses.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Tevimbra, BGBA-317
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1), PD-L1 (CD274) (binding partner it blocks), PD-L2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.